Global Therapeutic Vaccines Market Distribution by Type of Vaccine, Method of Va… – Press Release


New York, May 24, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Therapeutic Vaccines Market Distribution by Type of Vaccine, Method of Vaccine Composition, Type of Therapy, Target Disease Indication, Route of Administration and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035” – https://www.reportlinker.com/p06280486/?utm_source=GNW
Therapeutic vaccines are not as efficacious as prophylactic vaccines; however, they demonstrate safety, specificity and a long-lasting response across various clinical conditions. These vaccines help the immune system in recognizing a foreign agent and are primarily being developed for viral infections and different types of cancer. Additionally, individuals who are affected with chronic infections but cannot produce enough efficient antibodies can be administered such vaccines. Currently, six therapeutic vaccines are commercially available, including Imlygic®, Provenge® and Tice® which have recently been approved for treatment of melanoma, prostate cancer and bladder cancer, respectively; in addition, over 350 vaccines are under development for various oncological, infectious, hepatological, neurological and autoimmune disorders.

Extensive research is being conducted to improve the overall stability of these therapeutic formulations and a variety of adjuvants (substances with an innate potential to augment an immune response) have been discovered for the development of more versatile vaccine formulations. Further, researchers are also investigating the potential of these vaccines against other chronic disease conditions, including hypertension and autoimmune disorders. Over the last few years, this segment of industry has witnessed substantial partnership activity and investment from various private and public sector investors / investment funds, which have extended financial support to the organizations engaged in R&D. Driven by encouraging clinical trial…